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ETATE-OF-THE-ART PAPER683Stroke Prevention and Treatmentames D. Marsh, Salah G. Keyrouz
arsh and Keyrouz review several interventions for their utility in preventing strokes
s well as new strategies to treat acute strokes. The evidence supporting aggressive
ipid lowering in those with diabetes and for those with a prior stroke or transient
schemic attack is summarized. The current optimal anticoagulation and antiplatelet
herapy for stroke prevention is reviewed as is the data for both carotid stenting and
arotid endarterectomy. Notable advances in the acute treatment of stroke are
eviewed, including expanding the time window for thrombolysis from 3.0 to 4.5 h
nd the rapidly evolving data on intra-arterial thrombolysis and mechanical thrombus
xtraction.CLINICAL RESEARCH LINICAL TRIAL692No Benefit for Sertraline in HF Patients With Depressionhristopher M. O’Connor, Wei Jiang, Maragatha Kuchibhatla, Susan G. Silva, Michael S. Cuffe,
wayne D. Callwood, Bosh Zakhary, Wendy Gattis Stough, Rebekka M. Arias, Sarah K. Rivelli,
anga Krishnan, for the SADHART-CHF Investigators
epression is common among heart failure (HF) patients and is associated with increased
ospitalization and mortality. The SADHART-CHF (Sertraline Against Depression and
eart Disease in Chronic Heart Failure) trial tested the hypothesis that HF patients treated
ith sertraline would have lower depression scores and fewer cardiovascular events. It was
esigned as a randomized, double-blind, placebo-controlled trial of patients with left
entricular ejection fraction 45%, New York Heart Association functional class II to IV,
nd clinical depression. The primary end points were depression severity (Hamilton
epression Rating Scale [HDRS]) and composite cardiovascular status at 12 weeks. Both
lacebo and sertraline-treated patients had significant improvements in the HDRS, but there
as no difference between the two. There was no difference in cardiac status. These results
how that sertraline is safe in patients with significant HF, but it does not appear to be
eneficial.
ditorial Comment: Sarah J. Goodlin, p. 700(continued on page A-19)
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hARDIAC IMAGING702Exposure to Ionizing Radiation From Cardiac Proceduresersey Chen, Andrew J. Einstein, Reza Fazel, Harlan M. Krumholz, Yongfei Wang, Joseph S. Ross,
enry H. Ting, Nilay D. Shah, Khurram Nasir, Brahmajee K. Nallamothu
hen and colleagues used data from a large insurance company to calculate the radiation
xposure from cardiac imaging procedures in nearly 1 million subjects age 18 to 64 years.
early 10% underwent at least 1 cardiac imaging procedure using radiation. These patients
ad a mean cumulative effective dose over 3 years of 16.4 mSv. Myocardial perfusion imaging
ccounted for 74% of the cumulative effective dose. The annual population-based rate of
eceiving an effective dose of 3 to 20 mSv/year was 89.0 per 1,000, and it was 3.3 per 1,000
or cumulative doses 20 mSv/year. Cardiac imaging procedures lead to substantial radiation
xposure for many patients in the U.S.ditorial Comment: Matthew J. Budoff, Mohit Gupta, p. 712CHISTOSOMIASIS HEART DISEASE715Clinical Outcomes in Patients With Schistosomiasis-Associated PAHaio Julio Cesar dos Santos Fernandes, Carlos Vianna Poyares Jardim, Andre Hovnanian,
usana Hoette, Bruno Arantes Dias, Silvia Souza, Marc Humbert, Rogerio Souza
ulmonary arterial hypertension (PAH) is one of the most severe complications of chronic
chistosomiasis (Sch); it occurs in approximately 5% of patients with hepatosplenic
chistosomiasis mansoni. dos Santos Fernandes and colleagues compared the natural history
f untreated Sch-PAH patients to those with idiopathic pulmonary arterial hypertension
IPAH). Sch-PAH patients (n  54) had lower pulmonary vascular resistance, mean
ulmonary artery pressure, and higher cardiac output at presentation. None of the Sch-PAH
atients demonstrated a positive response to acute vasodilator testing, whereas 16% of IPAH
atients did. The 3-year survival did not differ between the cohorts. Data such as this will
elp to guide therapy in patients with Sch-PAH.(continued on page A-20)
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armen Perez-Terzic, Vinciane Gaussin, Christian Homsy, Jozef Bartunek, Andre Terzic
ehfar and colleagues describe their efforts to guide bone marrow-derived human
esenchymal stem cells (hMSCs) into a cardiac progenitor phenotype. The authors noted
hat hMSCs derived from some human donors were more effective than others and identified
ertain characteristics of these cells. A recombinant cocktail was formulated that stimulated
hese characteristics, and further studies confirmed that this cocktail facilitated cardiopoiesis.
ells treated with this cocktail were then injected into the myocardium of a nude infarcted
urine model and followed over 1 year. Compared with unguided counterparts, cardiopoietic
MSCs produced superior functional and structural benefit. Guided cardiopoiesis may
nhance the therapeutic benefit of hMSCs in chronic ischemic cardiomyopathy.ditorial Comment: Eduardo Marba´n, Konstantinos Malliaras, p. 735NEWS FROM THE NHLBI EWS FROM THE NHLBI738INTERMACS: A New Paradigm for Translating Registry Data Into Clinical Practicearissa A. Miller, Karen Ulisney, J. Timothy Baldwin
n this report from the National Heart, Lung, and Blood Institute (NHLBI), Miller and
olleagues describe the rationale for the Institute’s support of clinical registries. The purpose
f these registries is to efficiently and effectively translate clinical knowledge into improved
linical outcomes. The first of these registries is INTERMACS (Interagency Registry for
echanically Assisted Circulatory Support) for patients with mechanical circulatory support
MCS) devices, which was launched in 2006. By 2010, INTERMACS had over 100
articipating hospitals and more than 2,000 patients entered into the registry. Data from this
egistry is distributed to participating institutions on a quarterly basis. This registry speeds the
ractical adoption of evidence into clinical practice, provides a means for post-market
urveillance of devices, and supports research on comparative effectiveness, clinical care, and
atient management involving MCS devices.
